Declining CA-125 in an Ovarian Cancer Patient with Progression of Measurable Disease: A Rational Hypothesis for Discordant Results

Author： Markman M. Kennedy A. Webster K. Peterson G. Kulp B. Belinson J.

Publisher： Elsevier

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.77, Iss.2, 2000-05, pp. : 321-322

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Myth of Measurable Disease in Ovarian Cancer: Revisited

By Markman Maurie

Cancer Investigation, Vol. 27, Iss. 1, 2009-01 ,pp. : 11-12

Informa Healthcare

Access to resources Recommend Favorite

Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer

By Granato Teresa

Tumor Biology, Vol. 33, Iss. 5, 2012-10 ,pp. : 1335-1339

Springer Publishing Company

Access to resources Recommend Favorite

The Relationship between Postoperative Decline of Serum CA 125 Levels and Size of Residual Disease after Initial Surgery in Patients with Advanced Ovarian Cancer: A CTF Study

By Gadducci A. Landoni F. Maggino T. Sartori E. Zola P. Fanucchi A.

Gynecologic Oncology, Vol. 63, Iss. 2, 1996-11 ,pp. : 234-237

Academic Press

Access to resources Recommend Favorite

Effects of Paclitaxel on CA-125 Serum Levels in Ovarian Cancer Patients

By Paulsen T. Marth C. Kaern J. Nustad K. Kristensen G.B. Trope C.

Gynecologic Oncology, Vol. 76, Iss. 3, 2000-03 ,pp. : 326-330

Elsevier

Access to resources Recommend Favorite

Effect of Topotecan on Serum CA-125 in Patients with Advanced Epithelial Ovarian Cancer

By Nielsen H.A. Nielsen D. Engelholm S.A.

Gynecologic Oncology, Vol. 77, Iss. 3, 2000-06 ,pp. : 383-388

Elsevier

Access to resources Recommend Favorite